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Abstract
Background: Sirolimus (SRL, Rapamycin) has been used successfully to inhibit restenosis both in drug eluting stents
(DES) and after systemic application. The current study reports on the effects of SRL in various human in vitro/ex vivo
models and evaluates the theoretical clinical relevance of the data by SI/MPL- and SI/DES-ratio's.
Methods: Definition of the SI/MPL-ratio: relation between significant inhibitory effects in vitro/ex vivo and the maximal
plasma level after systemic administration in vivo (6.4 ng/ml for SRL). Definition of the SI/DES-ratio: relation between
significant inhibitory effects in vitro/ex vivo and the drug concentration in DES (7.5 mg/ml in the ISAR drug-eluting stent
platform). Part I of the study investigated in cytoflow studies the effect of SRL (0.01–1000 ng/ml) on TNF-α induced
expression of intercellular adhesion molecule 1 (ICAM-1) in human coronary endothelial cells (HCAEC) and human
coronary smooth muscle cells (HCMSMC). Part II of the study analysed the effect of SRL (0.01–1000 ng/ml) on cell
migration of HCMSMC. In part III, IV, and V of the study ex vivo angioplasty (9 bar) was carried out in a human organ
culture model (HOC-model). SRL (50 ng/ml) was added for a period of 21 days, after 21 and 56 days cell proliferation,
apoptosis, and neointimal hyperplasia was studied.
Results: Expression of ICAM-1 was significantly inhibited both in HCAEC (SRL ≥ 0.01 ng/ml) and HCMSMC (SRL ≥ 10
ng/ml). SRL in concentrations ≥ 0.1 ng/ml significantly inhibited migration of HCMSMC. Cell proliferation and neointimal
hyperplasia was inhibited at day 21 and day 56, significance (p < 0.01) was achieved for the inhibitory effect on cell
proliferation in the media at day 21. The number of apoptotic cells was always below 1%.
Conclusion: SI/MPL-ratio's ≤ 1 (ICAM-1 expression, cell migration) characterize inhibitory effects of SRL that can be
theoretically expected both after systemic and local high dose administration, a SI/MPL-ratio of 7.81 (cell proliferation)
represents an effect that was achieved with drug concentrations 7.81-times the MPL. SI/DES-ratio's between 10-6 and 10-
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8 indicate that the described inhibitory effects of SRL have been detected with micro to nano parts of the SRL
concentration in the ISAR drug-eluting stent platform. Drug concentrations in DES will be a central issue in the future.
Background
Sirolimus (SRL, rapamycin) was initially developed as an
antibiotic, then as an immunosuppressant, and recently
has been identified as one of the most promising novel
agents for prevention of human coronary restenosis, both
as the compound in drug eluting stents (DES) or after sys-
temic administration. Antimigratory and antiproliferative
properties of SRL were first described almost a decade ago
by Poon et al. [1] and Dell [2]. In a very short period of
time after these initial reports positive effects of SRL were
described in animal [3,4] and clinical restenosis studies,
using SRL eluting stents [5] or systemic administration
[6,7].
Human ex vivo organ culture models have the advantage
that the complexity of the restenosis process can be stud-
ied in coherent human arterial tissue [8-10]. In the human
renal organ culture model [[8], HOC-model] maximal
reactive cell proliferation occurs at day 21 after vascular
injury and maximal reactive intimal hyperplasia can be
detected at day 56. Recently Nührenberg et al. [11] used
the HOC-model to demonstrate that SRL in a concentra-
tion of 100 ng/ml combines antiproliferative and anti-
inflammatory properties.
There is now clear evidence for a contributory role of
inflammatory processes to restenosis following vascular
injury and stent implantation. Inflammatory cytokines
such as tumor necrosis factor-α (TNF-α) upregulate the
intercellular adhesion molecule-1 (ICAM-1). Our group
has demonstrated in a three-dimensional transfilter co-
culture model of leukocyte attack [12] that stimulation of
ICAM-1 expression increases adhesion and chemotaxis of
human monocytes and triggers reactive proliferation of
co-cultured human coronary smooth muscle cells.
Failed systemic restenosis trials in the 80ies and 90ies of
the past century have caused an estimated loss of 2.5 bil-
lion € to the pharmaceutical industry [13,14], indicating
the need for tools to predict the clinical relevance of posi-
tive in vitro data. Recently our group has suggested to
apply a SI/MPL-ratio, characterizing the relation between
a significant antiproliferative effect of a substance in vitro
(SI) and the maximal plasma level (MPL) of this sub-
stance after systemic administration [13,14]. A SI/MPL-
ratio < 1 characterizes an agent that has at least a theoret-
ical chance to achieve positive effects after systemic
administration (e.g. positive antiproliferative effects) and
after local high dose administration. If the SI/MPL-ratio is
> 1, it describes how many times the positive in vitro con-
centration is above the MPL. In this case the agent has a
mere local high dose option, e.g. in a drug eluting stent
(DES).
Recently a strong dose depending antiproliferative effect
of SRL in human coronary vascular cells has been reported
by our group [13]. The antiproliferative effect was
achieved with a SI/MPL-ratio's < 1, indicating that the
effect might theoretically be achieved both after systemic
and local high dose administration [13,14]. Data on the
effect of SRL on expression of ICAM-1 and migration in
human coronary vascular cells are missing, these issues
will be addressed in part I of the current study. In part II
of the study we will apply the ex vivo HOC-model to
investigate the effect of SRL on reactive cell proliferation,
apoptosis, and neointimal hyperplasia. Nührenberg et al.
[11] had already demonstrated that SRL in a concentra-
tion of 100 ng/mL (more than 10 times the maximal
plasma level after systemic administration, MPL) inhibits
proliferation and inflammation. In order to approach
more closely to the MPL we have investigated the effect of
SRL in a concentration of 50 ng/mL.
The current study investigates the effect of SRL on key
events of restenosis in a cascade of human in vitro and ex
vivo models. A theoretical clinical relevance of the data
will be characterized by SI/MPL- [13,14] and, for the first
time, by SI/DES-ratio's. The SI/DES-ratio describes the
relation between the drug concentration with a significant
inhibition in vitro or ex vivo (SI) and the drug concentra-
tion in a drug eluting stent (DES)
Methods
Cell isolation, cultivation and identification
Endothelial cells from human umbilical veins (HUVEC)
were isolated after vaginal delivery by enzymatic disaggre-
gation with collagenase/dispase as described previously
[15]. Endothelial cells from human coronary arteries
(HCAEC) were purchased at Cambrex Bio-products (Verv-
ier, B). Smooth muscle cells from the human coronary
media (HCMSMC) were purchased at Cambrex Bioprod-
ucts. Cells were cultured and identified as described [15].
Sirolimus
Sirolimus (SRL): Rapamycin®, Sigma, Deisenhofen, D,
0.01 – 1000 ng/ml, dilution: methanol; MPL: 6.4 ng/ml
[6].BMC Cardiovascular Disorders 2007, 7:15 http://www.biomedcentral.com/1471-2261/7/15
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Flow cytometry
For flow cytometry analysis of the expression of ICAM-1
in HCAEC, HUVEC, and HCMSMC cells were trypsinized
and seeded into 6-well dishes (5 × 104 cells). SRL (0.01,
0.1, 1, 10, 100, 1000 ng/ml) was added to the cultures for
a period of 18 h. During the last 6 h of SRL incubation, the
expression of adhesion molecules was stimulated by add-
ing of TNF-α (20 ng/mL).
After SRL/TNF-α treatment, cells were washed twice with
phosphate-buffered saline (pH 7.2) and trypsinized. Cells
were resuspended in 100 μL of a FITC-conjugated mono-
clonal antibody directed against ICAM-1 (clone 84H10,
Dianova Immunotech; final concentration 10 μg/mL) and
incubated for 20 min at 4°C. A total of 1 × 104 cells (100%
gated) were analyzed immediately with a flowcytometer
(BD FACSCalibur, Becton Dickinson, Heidelberg, D).
The effects of SRL (0.01 ng/mL – 1000 ng/mL) on vitality
of HCAEC, HUVEC, and HCMSMC was analyzed with
propidium iodide using a flowcytometer.
Boyden chamber
For cell migration studies a Boyden Chamber (QCM™ 24-
well colorimetric cell migration assay, Chemicon Europe,
UK) was used. HCMSMC were cultured for 48 h in SmBM-
culture medium with 1% fetal calf serum (fcs), thereafter
a cell supension with 4 × 104 cells/filter was produced.
300 μl of this suspension was added in serumfree medium
to the upper side of the filter, 500 μl supplemented with
10% fcs were added to the inferior side of the filter. The
Boyden Chamber was cultured for a period of 24 h, there-
after cells on the upper side of the filters were removed.
Filters were stained, dried, and incubated with extraction
buffer for 15 min. Finally the optical density was meas-
ured at 560 nm.
The human organ culture model (HOC-Model)
During routine-nephrectomies parts of renal arteries of 15
patients (ages: 66.5 ± 10 years, male/femal: 11/4) were
extracted, 15 arteries were suitable for organ culture prep-
arations. In the laboratory, renal artery segments were
carefully prepared and sections were made at 3 mm inter-
vals perpendicular to the vessel wall axis [8].
Ex vivo ballooning and adding of SRL
Ex vivo angioplasty was carried out as described [8]. After
ex vivo ballooning SRL (50 ng/ml) was added to the cul-
tures for a period of 21 days. At each medium exchange
the drug was renewed.
Cultivation and fixation of organ cultures
Cultivation and fixation of organ cultures was carried out
as described earlier [8]. Culture conditions for control
groups were exactly the same as described for the angi-
oplasty/SRL group.
Analysis of reactive cell proliferation, apoptosis, and neointimal 
thickening
The effect of SRL (50 ng/mL) on reactive cell proliferation,
apoptosis, and neointimal thickening [8] was studied at
day 21 and day 56 after ballooning, controls were per-
formed with and without ballooning. Due to the fact that
atheroslerosis was present in the vast majority of renal
arteries these atherosclerotic areas were defined as
"plaque-intima" and had to be differentiated from the
neointimal areas forming after angioplasty. The
neointima can be differed from the plaqueintima by the
very low density of the neointimal structures [8]. Prolifer-
ation (PCNA) and apoptosis (TUNEL-technique) of cells
was studied in the neointima, plaque-intima, and media.
Proliferation of cells was analyzed with the Proliferating
Cell Nuclear Antigen (PCNA). For immunohistological
staining paraffin sections were processed using a avidin-
biotin immunoperoxidase technique. PCNA-antibodies
(Dakopatts Hamburg, D) in a concentration of 1 μg/ml
were used as primary antibodies. The number of prolifer-
ating cells was calculated as: PCNA positive cells/total cell
number × 100.
Apoptotic cells were detected with the TUNEL-technique
(in situ cell detection kit, Roche, Mannheim, D) according
the manufactures's instructions. The number of apoptotic
cells was calculated as: apoptotic cells/total cell number ×
100.
SI/MPL-ratio
The SI/MPL-ratio was calculated in order to describe the
relation between a significant inhibitory effect in vitro
and the maximal plasma level after systemic administra-
tion in vivo [13,14].
SI/DES-ratio
The SI/DES-ratio was calculated in order to describe the
relation between a significant inhibitory effect in vitro
and the drug concentration in a DES.
Statistical analysis
Data of flow cytometry and migration studies were pre-
sented as mean ± S.D. Statistical significance of differences
between controls and drug-treated cells was determined
by paired Student's t-test. The Mann-Whitney rank-sum
test was used to investigate the significance of differences
in the human organ culture model. Statistical significance
was accepted for P < 0.05.BMC Cardiovascular Disorders 2007, 7:15 http://www.biomedcentral.com/1471-2261/7/15
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Results
Identification of HCAEC, HUVEC, and HCMSMC
Monocultures of HCAEC and HUVEC were identified by
positive reaction with antibodies directed against von Wil-
lebrand factor and the typical "cobblestone" growth pat-
tern in culture. Monocultures of HCMSMC exhibited the
"hill and valley" growth pattern and reacted positively
with antibodies against smooth muscle α-actin.
Effect of SRL on ICAM-1 expression in HCAEC, HUVEC, 
and HCMSMC
The effects of SRL (0.01, 0.1, 1, 10, 100, 1000 ng/ml) on
the TNF-α induced expression of ICAM-1 are demon-
strated in figure 1. A dose dependent significant inhibi-
tion of ICAM-1 expression was detected in HCAEC,
HUVEC, and HCMSMC. In comparison to HCMSMC the
inhibitory effect of SRL on ICAM-1 expression was pro-
nounced in both HCAEC and HUVEC.
In HCAEC, treatment with TNF-α increased the mean flu-
orescence levels (%) of ICAM-1 expression 18.83-fold
from 5.31% to 100.00%. Incubation of HCAEC with SRL
caused a dose dependent inhibition of ICAM-1 expres-
sion. After incubation with SRL in concentrations of 0.01,
0.1, and 1 ng/ml expression of ICAM-1 was significantly
decreased by 1.13% (p < 0.05), 8.9% (p < 0.05), and
25.73% (p < 0.05), corresponding to SI/MPL-ratio's of
1.563 × 10-3, 1.563 × 10-2, 0.1563 and SI/DES-ratio's of
1.3 × 10-9, 1.3 × 10-8, 1.3 × 10-7. Incubation of HCAEC
with SRL in concentrations of 10, 100, and 1000 ng/mL
caused an decrease by 36.92% (p < 0.01), 35.4% (p <
0.01), and 38.4% (p < 0.05), corresponding to SI/MPL-
ratio's of 1.563 × 10-2, 0.1563, 1.563 and SI/DES-ratio's of
1.3 × 10-8, 1.3 × 10-7, 1.3 × 10-6.
In HUVEC, treatment with TNF-α increased the mean flu-
orescence levels (%) of ICAM-1 expression 39.53-fold
from 2.53% to 100.00%. Incubation of HUVEC with SRL
in concentrations of 0.01 ng/ml and 0.1 ng/ml caused a
small stimulatory effect of 2.7% (n.s.) and a small inhibi-
tory effect of 2.22% (n.s.). After incubation of HUVEC
with SRL in concentrations of 1, 10, 100, and 1000 ng/ml
expression of ICAM-1 was inhibited by 13.76% (p =
0.01), 29.85% (p < 0.01), 34.08% (p < 0.01), and 31.8%
(p < 0.01), corresponding to SI/MPL-ratio's of 0.1563,
0.01563, 0.1563, 1.56 and SI/DES-ratio's of 1.3 × 10-7, 1.3
× 10-8, 1.3 × 10-7, 1.3 × 10-6.
In HCMSMC, treatment with TNF-α increased the mean
fluorescence levels (%) of ICAM-1 expression 4.93-fold
from 20.29% to 100.00%. Incubation of HCMSMC with
SRL in concentrations of 0.01, 0.1, and 1 ng/ml caused a
small stimulatory effects of 4.37% (p < 0.05; SI/MPL-
ratio: 1.563 × 10-3; SI/DES-ratio: 1.3 × 10-9) and 0.43%
(n.s.) and a small inhibitory effect of 3.35% (n.s.). After
incubation of HCMSMC with SRL in concentrations of 10,
100, and 1000 ng/ml expression of ICAM-1 was inhibited
by 11.75% (p < 0.01; SI/MPL-ratio: 0.01563; SI/DES-
ratio: 1.3 × 10-8), 15.92% (p < 0.01; SI/MPL-ratio: 1.563 ×
10-2; SI/DES-ratio: 1.3 × 10-8), and 11.15% (n.s.).
The effects of SRL (0.01, 0.1, 1, 10, 100, 1000 ng/ml) on TNF- α induced expression of ICAM-1 are demonstrated Figure 1
The effects of SRL (0.01, 0.1, 1, 10, 100, 1000 ng/ml) on TNF-
α induced expression of ICAM-1 are demonstrated. A dose 
dependent significant inhibition of ICAM-1 expression was 
detected in HCAEC (SRL ≥ 0.01 ng/ml), HUVEC (SRL ≥ 1 ng/
ml), and HCMSMC (SRL ≥ 10 ng/ml).
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Effect of SRL on migration of HCMSMC
The effects of SRL (0.01, 0.1, 1, 10, 100, 1000 ng/ml) on
migration of HCMSMC are demonstrated in figure 2. A
significant inhibition of cell migration was detected after
adding of SRL in concentrations ≥ 0.1 ng/ml (SI/MPL-
ratio ≥ 0.016; SI/DES-ratio ≥ 1.3 × 10-8).
After incubation of HCMSMC with SRL in concentrations
of 0.01, 0.1, and 1 ng/ml migration of HCMSMC was
inhibited by 15.74% (n.s.), 23.1% (p < 0.01), and 24.67%
(p < 0.001), corresponding to SI/MPL-ratio's of 1.563 ×
10-2, 0.1563 and SI/DES-ratio's of 1.3 × 10-8, 1.3 × 10-7.
Incubation of HCMSMC with SRL in concentrations of
10, 100, and 1000 ng/mL caused an decrease of cell migra-
tion of 32.09% (p < 0.01), 25.28% (p < 0.05), and
26.34% (p < 0.05), corresponding to SI/MPL-ratio's of
1.563 × 10-2, 0.1563, 1.563 and SI/DES-ratio's of 1.3 × 10-
8, 1.3 × 10-7, 1.3 × 10-7.
Effect of SRL on proliferation, apoptosis, and neointimal 
hyperplasia
In the current human ex vivo study the effect of 21 days
incubation with SRL (50 ng/ml) on reactive cell prolifera-
tion (Fig. 3), apoptosis (Fig. 4), and neointimal hyperpla-
sia (Fig. 5) was studied 21 days and 56 days after
ballooning. SRL inhibited both reactive cell proliferation
and reactive neointimal hyperplasia, statistical signifi-
cance was achieved merely for the inhibitory effect on cell
proliferation in the media at day 21. The number of apop-
totic cells was always very low and did not increase 1%.
21 days after angioplasty (n = 6) cell proliferation in the
neointima, plaque-intima, and the media was increased
by 11.89% (n.s.), 3.73% (n.s.), and 4.27% (n.s.) in com-
parison to cell proliferation before angioplasty. After incu-
bation with SRL (50 ng/ml) for a period of 21 days no cell
proliferation was detected in the neointima, cell prolifer-
ation in the plaque-intima and media was decreased by
93.3% (n.s.) and 95.78% (p < 0.01; SI/MPL-ratio: 7.81).
56 days after angioplasty (n = 10) cell proliferation in the
human organ cultures was very low and did not increase
2%. In the neointima, plaque-intima, and media cell pro-
liferation was increased by 1.96% (n.s.), 1.25% (n.s.), and
0.23% (n.s.) in comparison to cell proliferation before
angioplasty and decreased by 70.41% (n.s.), 32% (n.s.),
and 52.17% (n.s.) after SRL incubation.
The number of apoptotic cells in the artery segments was
always very low and did not increase 1%. Apoptotic cells
was detected merely in the media, almost no apoptosis
was found in the neointima and plaque-intima. 21 days
after angioplasty (n = 6) apoptosis in the media was
increased by 0.18% (n.s.) in comparison to the percentage
of apoptotic cells before angioplasty, 56 days after angi-
oplasty by 0.64% (n.s.). Incubation with SRL caused both
stimulating and inhibiting effects. At day 21 the number
of apoptotic cells was increased by 52.6% in comparison
to the angioplasty group (n.s.), at day 56 inhibited by
42.19% (n.s.).
The effects of SRL (0.01, 0.1, 1, 10, 100, 1000 ng/ml) on migration of HCMSMC are demonstrated Figure 2
The effects of SRL (0.01, 0.1, 1, 10, 100, 1000 ng/ml) on migration of HCMSMC are demonstrated. A significant inhibition of cell 
migration was detected after adding of SRL in concentrations ≥ 0.1 ng/ml (* = p < 0.5; ** = p < 0.01; *** = p < 0.001; SI/MPL-
ratio ≥ 0.016; SI/DES-ratio ≥ 1.3 × 10-8).
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Neointimal hyperplasia after angioplasty was increased by
1.44% at day 21 (n = 5) and 6.11% at day 56 (n = 10) in
comparison to neointimal hyperplasia before angioplasty.
After a 21-days incubation with SRL (50 ng/ml) no
neointimal hyperplasia was detected at day 21 and a
reduction by 31.26% was detected at day 56 (n.s.).
Discussion
The current study reports on the effects of SRL in various
human in vitro/ex vivo models and evaluates the theoret-
ical clinical relevance of the data by SI/MPL- and SI/DES-
ratio's.
Expression of ICAM-1 is one of the crucial events for adhe-
sion and chemotaxis of human monocytes from the circu-
lating blood into the coronary artery wall. In the current
study TNF-α induced expression of ICAM-1 was signifi-
cantly inhibited by SRL both in endothelial and smooth
muscle cells. The corresponding SI/MPL-ratio's of
0.00156 (HCAEC), 1.56 (HCMSMC), and 0.156
(HUVEC) indicate that the inhibitory effects may be
expected theoretically both after systemic and local high
dose administration. In contrast to the current data Min-
hajuddin et al. [16] reported that SRL in a concentration
of 5 ng/ml inhibits mammalian target of rapamycin
(mTOR) but stimulates thrombin-induced expression of
ICAM-1 in endothelial cells. In the current study SRL con-
centrations of 1 ng/ml and 10 ng/ml inhibited expression
of ICAM-1 both in endothelial and smooth muscle cells.
Surprisingly, a small stimulatory effect on ICAM-1 expres-
sion was detected in HCMSMC after incubation with SRL
in a concentration of 0.01 ng/ml. The contrasting data
may be partially explained by the fact that Minhajuddin et
al. [16] reported on the effect of thrombin-induced
expression of ICAM-1, whereas the current study
described the effect of TNF-α-induced ICAM-1 expression.
Moreover activation of ICAM-1 expression via NF-κB is
complicated by redundant pathways and differences exist
in endothelial cells and smooth muscle cells, as reported
earlier by our group [15]. Recently, a role of c-Jun N-ter-
minal kinase (JNK) in thrombin-induced ICAM-1 expres-
sion in endothelial cells was described, a mechanism that
is dependent on Gα, Gβγ, Rasw, Rac1, and the Src kinase
family [17].
In the current study migration of HCMSMC was inhibited
after administration of SRL in concentrations ≥ 0.1 ng/ml.
The corresponding SI/MPL-ratio of 0.016 indicates that
the antimigratory effect was achieved with 1.6% of the
maximal plasma level after oral application, resulting in
both a systemic and local high dose option for this effect.
These data are in accordance with data in the literature
[1,18]. Poon et al. [1] reported that pretreatment with SRL
in a concentration of 2 ng/mL inhibited PDGF-induced
In the ex vivo HOC-model the effect of a 21 days incubation with SRL (50 ng/ml) on reactive cell proliferation was studied in  the neointima, plaque-intima, and media at day 21 and day 56 Figure 3
In the ex vivo HOC-model the effect of a 21 days incubation with SRL (50 ng/ml) on reactive cell proliferation was studied in 
the neointima, plaque-intima, and media at day 21 and day 56. SRL inhibited reactive cell proliferation, statistical significance 
was achieved for the inhibitory effect on cell proliferation in the media at day 21 (SI/MPL-ratio: 7.81).
0
5
10
15
20
25
30
35
40
45
50
C balloon treated 50 ng/ml S
21
d
56
d
Neointima
0
5
10
15
20
25
30
35
40
45
50
C balloon treated 50 ng/ml S
0
5
10
15
20
25
30
35
40
45
50
C balloon treated 50 ng/ml S
Plaque-Intima
0
5
10
15
20
25
30
35
40
45
50
C balloon treated 50 ng/ml S
0
5
10
15
20
25
30
35
40
45
50
C balloon treated 50 ng/ml S
0
5
10
15
20
25
30
35
40
45
50
C balloon treated 50 ng/ml S
Media
P
C
N
A
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
(
%
)BMC Cardiovascular Disorders 2007, 7:15 http://www.biomedcentral.com/1471-2261/7/15
Page 7 of 10
(page number not for citation purposes)
migration of rat aortic smooth muscel cells in a modified
Boyden chamber. Sakakibara et al. [18] reported that SRL
in a concentration of 10 nM (corresponding to a concen-
tration of 9.14 ng/ml) markedly diminuished fibronectin
induced migration of a rat aortic smooth muscle cells and
of a human arterial smooth muscle cell line (E47).
According to the authors the fibronectin induced migra-
tion of rat and human smooth muscle cells may be inhib-
ited through a pathway that involves at least
alpha(v)beta[3]-integrin, phosphatidylinositol 3-kinase
(PI3K), the mammilian target of rapamycin (mTOR), and
S6 kinase (S6K). Migration in the current study was car-
ried out in a Boyden chamber against culture medium
with 10% fetal calf serum, therefore it's not clear whether
the medium contained fibronectin or not. The missing
dose dependency in the current study is difficult to
explain. Poon et al. [1] and Sakakibara et al. [18]
described an inhibitory effect of SRL on PDGF-induced
[1] respectively fibronectin-induced [18] migration of rat
aortic smooth muscle cells. Both groups did not investi-
gate the effect of various SRL concentrations. In contrast to
the current data Parry et al. [19] reported that low concen-
trations of sirolimus inhibited merely cell proliferation
and not cell migration.
In the ex vivo part of the study the effect of SRL in a con-
centration of 50 ng/ml on cell proliferation, apoptosis,
and neointimal hyperplasia was studied. An antiprolifera-
tive effect of SRL on cell proliferation was first described
by Dell [2]. Marx et al. [20] reported of a significant inhib-
itory effect of SRL in a concentration of 1 ng/ml in SMC
from rat and human aorta (SI/MPL-ratio: 0.16). These
data were confirmed later by data of our group with
human coronary smooth muscle cells [[13]; SI/MPL-ratio:
0.16]. Recently Nührenberg et al. [11] reported of a signif-
icant antiproliferative effect of SRL in a concentration of
100 ng/ml in the HOC-model at day 21 after angioplasty
(SI/MPL-ratio: 15.63). In accordance with these reports
the current study describes a significant antiproliferative
effect of SRL in a concentration of 50 ng/ml in the HOC-
model at day 21 after angioplasty (SI/MPL-ratio: 7.81).
Both the ex vivo study of Nührenberg et al. [11] and the
current ex vivo data were carried out with drug concentra-
tions 15.63-times respectively 7.81-times the MPL. There-
fore these results merely prove the antiproliferative effect
of SRL in DES, not after systemic administration as the
prior in vitro studies of Marx [20] and our group [14].
Neointimal hyperplasia was inhibited after incubation
with SRL in a concentration of 50 ng/ml at day 21 and day
56, statistical significance was not achieved. These data are
in accordance with many reports in rabbit [21] and por-
cine [3,4] experimental models. Experimental respectively
ex vivo data of intimal hyperplasia correspond to a certain
The effect of incubation of the ex vivo HOC-model with SRL (50 ng/ml) on apoptosis was studied in the neointima, plaque- intima, and media at day 21 and day 56 Figure 4
The effect of incubation of the ex vivo HOC-model with SRL (50 ng/ml) on apoptosis was studied in the neointima, plaque-
intima, and media at day 21 and day 56.
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degree to clinical angiographic restenosis data. However
due to the fact that the current study was carried out with
a concentration of SRL 7.81-times the MPL after oral
administration of SRL, it can merely be compared with
clinical studies with SRL-eluting stents [5] and not with
studies describing the effect of oral application [6,7].
Apoptotic effects did not play a major role in the resteno-
sis process of the HOC-model, the number of apoptotic
cells never increased 1%. In contrast to the current data
apoptotic cell death has been documented in numerous
animal models of vascular injury [22-24]. Pollman et al
[23] reported that the rapid wave of apoptosis resulting
from vascular injury appears to involve a redox sensitive
pathway, because local administration of antioxidants has
minimized cell loss. Normocholesterolemic and hyperc-
holesterolemic rabbits display similar profile of early
postinjury apoptosis, but hypercholesterolemia enhances
apoptosis in the neointima at two weeks after injury [23].
This observation has led to the hypothesis that macro-
phages present in the vascular lesions of the hypercholes-
teremic rabbits may contribute to SMC turnover.
Macrophage involvement has also been implicated in
apoptosis observed after stent implantation in rabbit ves-
sels [25].
In the literature the amount of SRL in DES is described as
μg/stent or μg/mm2, informations that are useless for a
correlation with in vitro/ex vivo drug concentrations. To
our best knowledge the only exception is a report of
Wessely et al. [26], describing SRL concentrations of 7.5
mg/ml in the ISAR drug eluting stent platform. The rela-
tion between the significant inhibitory effects in the cur-
rent study and the drug concentrations in the ISAR drug-
eluting stent platform results in SI/DES-ratio's of 10-6 and
10-8.
Limitations of the study
The adhesion molecule ICAM-1 is merely one of a large
number of inflammation markers. In the current study we
focused on expression of ICAM-1 because our laboratory
has already characterized precisely the TNF-α induced
stimulation of ICAM-1 expression in HCAEC, HUVEC,
and HCMSMC [27].
Although ex vivo models are very attractive they are ham-
pered by high standard deviations due to the preparation
procedure [8]. The arteries are cut at the frontal sides and
the adventitial side. Balloon injury is merely one addi-
tional stimulus in this activated situation. If the ex vivo
HOC-model is used to study the effect of agents on key
events of restenosis, significant differences to untreated
controls cannot be achieved.
SI/MPL- and SI/DES-ratio's are merely a theoretical help
to evaluate the clinical relevance of in vitro/ex vivo data.
Conclusion
SI/MPL-ratio's ≤ 1 (ICAM-1 expression, cell migration)
characterize inhibitory effects of SRL that can be theoreti-
cally expected both after systemic and local high dose
administration, a SI/MPL-ratio of 7.81 (cell proliferation)
represents an effect that was achieved with drug concen-
trations 7.81-times the MPL. SI/DES-ratio's between 10-6
and 10-8 indicate that the described inhibitory effects of
SRL have been detected with micro to nano parts of the
SRL concentration in the ISAR drug-eluting stent plat-
form. It remains to be elucidated whether SRL concentra-
tions in DES can be drastically reduced without loosing
the convincing anti-restenotic effects in vivo.
Due to the fact that the application of the SI/MPL-ratio
[13,14] might have stopped many negative systemic rest-
enosis trials in the 80ies and 90ies, saving an estimated
loss of 2.5 billion € of the pharmaceutical industry [14],
the usefulness of the SI/MPL-ratio is convincing. Due to
antiproliferative SI/MPL-ratio's > 1, prednisolone (SI/
MPL-ratio: 7.1; 28), dexamethasone (SI/MPL-ratio: 6.6;
28), cyclosporine A (SI/MPL-ratio: 11.1; 29), iloprost (SI/
MPL-ratio: 10; 30), triazolopyrimidine (SI/MPL-ratio:
4.86; 31), diltiazem (SI/MPL-ratio: 104.2; 32), and abcix-
imab (SI/MPL-ratio: 11.4; 33) should not have been
applied in clinical studies rationally based on a significant
antiproliferative effect. Antiproliferative SI/MPL-ratio's <
1 have been reported of the cytostatic agents cytarabine
(SI/MPL-ratio: 0.1; 34), doxorubicine (SI/MPL-ratio: 0.83;
34), etoposide (SI/MPL-ratio: 0.0021; 34), paclitaxel (SI/
MPL-ratio: 0.002; 30) and of the immunosuppressive
agents hydrocortisone (SI/MPL-ratio: 0.043; 28),
In the ex vivo HOC-model the effect of 21 days incubation  with SRL (50 ng/ml) on neointimal hyperplasia was studied 21  days and 56 days after ballooning Figure 5
In the ex vivo HOC-model the effect of 21 days incubation 
with SRL (50 ng/ml) on neointimal hyperplasia was studied 21 
days and 56 days after ballooning. SRL inhibited neointimal 
hyperplasia, statistical significance was not achieved.
0
2
4
6
8
10
12
14
C balloon treated 50 ng S C balloon treated 50 ng S
N
e
o
i
n
t
i
m
a
 
(
%
)
21 d 56 dBMC Cardiovascular Disorders 2007, 7:15 http://www.biomedcentral.com/1471-2261/7/15
Page 9 of 10
(page number not for citation purposes)
sirolimus (SI/MPL-ratio: 0.01; 13), and mycophenolate
mofetil (SI/MPL-ratio: 0.0011; 13). These agents have at
least a theoretical chance to reproduce an antiproliferative
effect after systemic administration.
The application of a SI/DES-ratio is suggested for the first
time in the current study. Drug concentrations in current
DES are extremely high [26], resulting in SI/DES ratio's
between 10-6 and 10-8. This is overdone and may partially
cause the problems of late thrombosis in DES [35]. Prob-
ably antiproliferative SI/DES-ratio's between 10-1 to 10-2
are sufficient to create a significant local antiproliferative
effect.
Drug concentrations in DES will be the central issue of the
future. It has to be demonstrated, if the SI/DES-ratio can
close a little bit the gap between bench and bedside by
keeping the focus on the relation between effective drug
concentrations in vitro and the local concentration in
DES.
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